Danaher Corporation

DHR

US2358511028

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:02 2025-06-11 pm EDT			5-day change	1st Jan Change
204.72 ^USD	+1.04%		+6.03%	-10.82%

Jun. 09	Some of the biggest splits in Corporate America	RE
Jun. 09	Some of the biggest splits in Corporate America	RE

UBS Adjusts Danaher Price Target to $240 From $275, Maintains Buy Rating

Published on 04/23/2025 at 10:17, updated on 04/23/2025 at 10:18

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Danaher Corporation

Some of the biggest splits in Corporate America	Jun. 09	RE
Some of the biggest splits in Corporate America	Jun. 09	RE
Deutsche Bank Adjusts Danaher Price Target to $235 From $240	Jun. 05	MT
Sciex And Evosep Expand Access To Standardized Proteomics For Pharma And Biotech With New Reseller Agreement	Jun. 02	RE
Software Launches For Sciex Os Ecosystem	Jun. 02	RE
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools	May. 30	MT
Danaher partners with AstraZeneca to develop AI diagnostics	May. 30	AN
Danaher Announces Diagnostic Development And Commercialization Partnership To Scale Precision Medicine	May. 29	RE
Danaher, AstraZeneca Collaborate on Precision Medicine	May. 29	MT
Danaher Corporation Announces the Launch of Partnership with AstraZeneca to Develop and Commercialize Novel Diagnostic Tools and Tests Intended to Help Clinicians Better Determine Which Patients Would Most Benefit from Precision Medicine Treatments	May. 29	CI
Danaher, AstraZeneca Form Partnership For Diagnostic Development	May. 29	DJ
Third Point LLC Dissolves Share Stake In Meta, Thermo Fisher Scientific & Cuts Share Stake In Microsoft	May. 15	RE
Danaher Corporation Presents at BofA Securities 2025 Healthcare Conference, May-15-2025 10:00 AM	May. 15
Danaher Insider Sold Shares Worth $245,919,391, According to a Recent SEC Filing	May. 14	MT
Third Point Investors says fund down in first quarter amid tariffs	May. 02	AN
Danaher Insider Sold Shares Worth $3,129,424, According to a Recent SEC Filing	May. 01	MT
Veralto posts upbeat first-quarter results, shares up	Apr. 29	RE
Danaher Unit Signs Joint Marketing Deal With Kytopen for Cell Therapy Manufacturing Product	Apr. 29	MT
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook	Apr. 28	RE
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook	Apr. 28	RE
HSBC Adjusts Danaher Price Target to $240 From $270	Apr. 25	MT
Argus Cuts Price Target on Danaher to $240 From $260	Apr. 23	MT
UBS Adjusts Danaher Price Target to $240 From $275, Maintains Buy Rating	Apr. 23	MT
TD Cowen Adjusts Price Target on Danaher to $248 From $240, Maintains Buy Rating	Apr. 23	MT
Barclays Adjusts Price Target on Danaher to $215 From $205, Maintains Overweight Rating	Apr. 23	MT

Danaher Corporation is an industrial and technologic group organized around two families of products: - medical equipment (70.1% of net sales): diagnostic equipment, digital imaging systems, optical instruments, microscopes, consumables, etc.; - professional instruments of analysis (29.9%): systems of quality control of waters, disinfection, etc. Net sales are distributed geographically as follows: the United States (40.1%), China (13.2%) and other (46.7%).

Employees

62,000

Sector

Advanced Medical Equipment & Technology

Calendar

Jun. 26 - Détachement de

More about the company